GENSET/GENETHON JOINT VENTURE FOR HUMAN GENOME SEQUENCING
Executive Summary
GENSET/GENETHON JOINT VENTURE FOR HUMAN GENOME SEQUENCING will give Paris-based Genset commercial rights to any applications arising from efforts to sequence and analyze the regulatory regions of the human genome. The agreement, announced June 29, calls for Genset and the French research center Genethon to form the Tres Grand Sequencage laboratory that will be funded by an initial commitment of $11 mil. from both parties, including a $2 million equity participation in Genset made by Genethon.